123 related articles for article (PubMed ID: 38395838)
1. Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy.
Chen K; Li S; Chen M; Jin Z; Sun X; Zhou S; Yang H
BMC Cancer; 2024 Feb; 24(1):257. PubMed ID: 38395838
[TBL] [Abstract][Full Text] [Related]
2. Five-year survival rate analysis: the combination of fortnightly-administration of endostar and concurrent chemoradiotherapy versus concurrent chemoradiotherapy in the treatment of inoperable locally advanced non-small cell lung cancer.
Ma H; Peng F; Xu Y; Bao Y; Hu X; Wang J; Fang M; Kong Y; Dong B; Chen M
Ann Palliat Med; 2021 Jul; 10(7):7560-7570. PubMed ID: 34353044
[TBL] [Abstract][Full Text] [Related]
3. Endostar (rh-endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis.
Yuan M; Zhai Y; Men Y; Wang J; Deng L; Wang W; Bao Y; Yang X; Sun S; Ma Z; Liu Y; Wang J; Zhu H; Hui Z
Thorac Cancer; 2021 Dec; 12(23):3208-3215. PubMed ID: 34676669
[TBL] [Abstract][Full Text] [Related]
4. Endostar improved efficacy of concurrent chemoradiotherapy with vinorelbine plus carboplatin in locally advanced lung squamous cell carcinoma patients with high serum Lp(a) concentration.
Xu H; Lv D; Meng Y; Wang M; Wang W; Zhou C; Zhou S; Chen X; Yang H
Ann Palliat Med; 2020 Mar; 9(2):298-307. PubMed ID: 32075401
[TBL] [Abstract][Full Text] [Related]
5. Symptomatic Radiation Pneumonitis in NSCLC Patients Receiving EGFR-TKIs and Concurrent Once-daily Thoracic Radiotherapy: Predicting the Value of Clinical and Dose-volume Histogram Parameters.
Yang X; Mei T; Yu M; Gong Y
Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):409-419. PubMed ID: 35747920
[TBL] [Abstract][Full Text] [Related]
6. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
[TBL] [Abstract][Full Text] [Related]
7. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.
Honglian M; Zhouguang H; Fang P; Lujun Z; Dongming L; Yujin X; Yong B; Liming X; Yirui Z; Xiao H; Jin W; Yue K; Lvhua W; Ming C
Thorac Cancer; 2020 Apr; 11(4):898-906. PubMed ID: 32068962
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Thymosin α1 in Management of Radiation Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiotherapy: A Phase 2 Clinical Trial (GASTO-1043).
Liu F; Qiu B; Xi Y; Luo Y; Luo Q; Wu Y; Chen N; Zhou R; Guo J; Wu Q; Xiong M; Liu H
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(3):433-443. PubMed ID: 35870709
[TBL] [Abstract][Full Text] [Related]
9. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
[TBL] [Abstract][Full Text] [Related]
10. Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab.
Shaverdian N; Thor M; Shepherd AF; Offin MD; Jackson A; Wu AJ; Gelblum DY; Yorke ED; Simone CB; Chaft JE; Hellmann MD; Gomez DR; Rimner A; Deasy JO
Cancer Med; 2020 Jul; 9(13):4622-4631. PubMed ID: 32372571
[TBL] [Abstract][Full Text] [Related]
11. Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A systematic literature review and meta-analysis.
Kuang Y; Pierce CM; Chang HC; Sosinsky AZ; Deitz AC; Keller SM; Samkari A; Uyei J
Lung Cancer; 2022 Dec; 174():174-185. PubMed ID: 35717343
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab.
Shintani T; Kishi N; Matsuo Y; Ogura M; Mitsuyoshi T; Araki N; Fujii K; Okumura S; Nakamatsu K; Kishi T; Atsuta T; Sakamoto T; Narabayashi M; Ishida Y; Sakamoto M; Fujishiro S; Katagiri T; Kim YH; Mizowaki T
Clin Lung Cancer; 2021 Sep; 22(5):401-410. PubMed ID: 33678582
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis.
Zhang SL; Han CB; Sun L; Huang LT; Ma JT
Radiat Oncol; 2020 Aug; 15(1):205. PubMed ID: 32831120
[TBL] [Abstract][Full Text] [Related]
14. Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis.
Sugimoto T; Fujimoto D; Sato Y; Tamiya M; Yokoi T; Taniguchi Y; Hino A; Hata A; Uchida J; Fukuda Y; Hara S; Kanazu M; Matsumoto H; Kokubo M; Yamamoto N
Lung Cancer; 2022 Sep; 171():3-8. PubMed ID: 35863254
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.
Zhu J; Chen G; Niu K; Feng Y; Xie L; Qin S; Wang Z; Li J; Lang S; Zhuo W; Chen Z; Sun J
Future Oncol; 2022 Mar; 18(9):1077-1087. PubMed ID: 34986655
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Efficacy and Toxicity of Concurrent Chemoradiotherapy and Durvalumab and Concurrent Chemoradiotherapy Alone for Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Metastasis.
Abe T; Iino M; Saito S; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki YU; Miura YU; Kaira K; Kagamu H; Noda SE; Kato S
Anticancer Res; 2023 Feb; 43(2):675-682. PubMed ID: 36697072
[TBL] [Abstract][Full Text] [Related]
17. Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study.
Jang JY; Kim SS; Song SY; Kim YJ; Kim SW; Choi EK
Radiat Oncol; 2021 Dec; 16(1):231. PubMed ID: 34863244
[TBL] [Abstract][Full Text] [Related]
18. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
Dieleman E; van der Woude L; van Os R; van Bockel L; Coremans I; van Es C; De Jaeger K; Knol HP; Kolff W; Koppe F; Pomp J; Reymen B; Schinagl D; Spoelstra F; Tissing-Tan C; van der Voort van Zyp N; van der Wel A; Wijsman R; Dielwart M; Wiegman E; Damhuis R; Belderbos J
Clin Lung Cancer; 2023 Mar; 24(2):130-136. PubMed ID: 36572596
[TBL] [Abstract][Full Text] [Related]
19. Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis.
Katsui K; Ogata T; Watanabe K; Katayama N; Soh J; Kuroda M; Kiura K; Maeda Y; Toyooka S; Kanazawa S
BMC Cancer; 2019 Nov; 19(1):1144. PubMed ID: 31771538
[TBL] [Abstract][Full Text] [Related]
20. Concurrent versus sequential chemoradiotherapy for unresectable locally advanced stage III non-small cell lung cancer: Retrospective analysis in a single United Kingdom cancer centre.
Spencer A; Williams J; Samuel R; Boon IS; Clarke K; Jain P
Cancer Treat Res Commun; 2021; 29():100460. PubMed ID: 34598059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
